Wellington Biomedical Innovation III Access Offshore LP has announced its intention to raise capital through a new offering, as detailed in its recent SEC filing. This move is crucial for the company as it seeks to attract private investments in the competitive investment fund landscape.

The company, incorporated in 2026, operates under the Central Index Key 0002160182. Wellington Biomedical Innovation III Access Offshore LP is classified as a limited partnership and is based in New York, with a business address at 200 West Street, New York, NY 10282-2198.

The filing, dated October 27, 2026, indicates that the company is utilizing Rule 506(b) for its offering, which provides a “safer harbor” for private offerings. The investment fund is categorized under pooled investment funds, specifically as an other investment fund, and is not registered under the Investment Company Act.

According to the filing, the total offering amount is indefinite, with no amount sold or remaining disclosed. The document specifies that the offering will last for more than one year and that there are no non-accredited investors involved at this stage.

Goldman Sachs & Co. LLC has been named as the sales recipient for this offering, which may enhance the company’s ability to reach potential investors across all states. The filing notes that the minimum investment accepted is $0, suggesting a flexible approach to attracting investors.

The filing does not specify what happens next, leaving the future steps in this capital-raising process open-ended. However, the involvement of a major financial institution like Goldman Sachs could indicate a strategic move to bolster investor confidence in the offering.